Gilead Sciences (GILD) Stock
Pharmaceutical giant with HIV hepatitis and cancer treatments. Here's the price, business snapshot, and what's worth knowing about Gilead Sciences in October 2026.
Gilead Sciences (GILD) is a large US biopharmaceutical company best known for antiviral medicines, including treatments for HIV and hepatitis, and therapies for COVID-19 and certain cancers. With a market capitalisation of about $153.96 billion, Gilead blends steady cash-generating legacy products with newer growth avenues such as cell therapies and oncology after strategic acquisitions. Investors should note the company’s reliance on a handful of high‑revenue drugs, exposure to patent expiries and pricing pressures, and the binary nature of clinical trial outcomes that can materially affect share price. Gilead pays a dividend and typically generates strong free cash flow, which can appeal to income-focused investors, but returns are not guaranteed. This summary is for educational purposes only and not personalised investment advice; consider your risk tolerance and time horizon, and consult a regulated adviser before making investment decisions.
Why It’s Moving
Gilead Shares Pull Back After Strong Run, Analysts Eye Mixed Signals
- GILD closed at $149.45, marking a -1.21% move from the previous day and underperforming the broader market.
- The stock has surged 35% since recent positive coverage, though analysts note that key growth catalysts have yet to fully materialize.
- Gilead remains a trending focus for retail investors, with high visibility on investment platforms indicating sustained interest despite short-term volatility.
Gilead Shares Pull Back After Strong Run, Analysts Eye Mixed Signals
- GILD closed at $149.45, marking a -1.21% move from the previous day and underperforming the broader market.
- The stock has surged 35% since recent positive coverage, though analysts note that key growth catalysts have yet to fully materialize.
- Gilead remains a trending focus for retail investors, with high visibility on investment platforms indicating sustained interest despite short-term volatility.
Sixth Month Growth Performance
When is the next earnings date for GILEAD SCIENCES INC (GILD)?
Gilead Sciences has not yet announced a confirmed date for its next earnings release. Based on the company's historical reporting pattern of approximately three months between quarters, the upcoming report is expected in late October 2026. This release will cover financial results for the third quarter of fiscal year 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Gilead's stock as it has potential for growth despite current price.
Financial Health
Gilead Sciences is performing well with strong profits, revenue, and cash flow generation.
Dividend
Gilead Sciences, with a dividend yield of 2.22%, offers a moderate return for dividend-seeking investors. If you invested $1000 you would be paid $32.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Antiviral Franchise
Strong HIV and hepatitis drugs deliver predictable revenues, though sales can be affected by competition and patent expiries.
Oncology & Cell Therapy
Newer programmes and acquisitions expand growth potential, but clinical and regulatory outcomes can be binary and affect valuations.
Cash Flow & Dividend
Solid cash generation supports a dividend and buybacks, yet income investors should remember dividends can change and are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
